Sensitivity (%) (95% CI)a | Specificity (%)(95% CI)a | ||
---|---|---|---|
N-staging | |||
Our review | PET (analyzed by patients) | 0 to 90 e | 18.2 to 100 e |
PET/CT (analyzed by patients) | 14 to 87 e | 95 to 100 e | |
Xing and colleagues [17] | PET (analyzed by patients and lesions; mixed)b | 30 (12 to 55) | 96 (87 to 99) |
PET/CT (analyzed by patients and lesions; mixed)b | 11 (1 to 50) | 97 (97 to 100) | |
Jimenéz-Requena and colleagues [14] | PET (analyzed by lymph nodes)b | – c | 99 (97 to 99) |
PET (analyzed by patients) | –c | –c | |
PET (analyzed by areas)b | –c | –c | |
M-staging | |||
Our review | PET (analyzed by patients) | 33 to 97 e | 56 to 98 e |
PET/CT (analyzed by patients) | 42 (15 to 72) d | 93 (81 to 99) d | |
Xing and colleagues [17] | PET (analyzed by patients and lesions; mixed)b | 74 (51 to 88) | 75 (45 to 91) |
PET/CT (analyzed by patients and lesions; mixed)b | 80 (53 to 93) | 87 (54 to 97) | |
Jimenéz-Requena and colleagues [14] | PET (analyzed by patients) | –c | –c |
PET (analyzed by lesions)b | – c | – c | |
PET (analyzed by areas)b | 86 (82 to 89) | – c | |
PET (analyzed by Scans)b | – c | 86 (77 to 92) | |
N-staging and M-staging | |||
Our review | PET(analyzed by patients) | 0 to 100 e | 18 to 100 e |
PET/CT (analyzed by patients) | 17 to 85 e | 74 to 96 e | |
Krug and colleagues [15] | PET (analyzed by patients, lesions and scans; mixed)b | 83 (81 to 84) | 85 (83 to 87) |
Mijnhout and colleagues [16] | PET (analyzed by patients, lesions and scans; mixed)b | 78 (70 to 84) | 88 (82 to 92) |